VivoSeq
Immunology

Autoimmune Pulmonary Alveolar Proteinosis

4

Pipeline Programs↗

3

Active Trials↗

3

Companies Involved↗

Autoimmune Pulmonary Alveolar Proteinosis is an early-stage landscape with 4 programs across 3 companies. The most active players are Takeda, Y-mAbs Therapeutics, Sanofi. 1 program is in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

28/100

Pipeline Velocity

6/100

Mech. Concentration

50/100

Completion Rate

75/100

Attrition Rate

10/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Takeda logo

Takeda

1 program

Phase 1Y

Y-mAbs Therapeutics

1 program

Phase 2Sanofi logo

Sanofi

1 program

Preclinical

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Protein / enzyme

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSSmall molecule133%

Protein / enzyme leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 100% of 4 pipeline programs.

Analysis

Trial Status

10

clinical trials

Completed3 · 30%
Unknown status2 · 20%
Active, not recruiting1 · 10%
Recruiting1 · 10%
Terminated1 · 10%
Not yet recruiting1 · 10%
Other1 · 10%

Clinical Trials

Trial Activity

10 trials

Inhaled Molgramostim in Pediatric Participants With Autoimmune Pulmonary Alveolar Proteinosis (aPAP).
Recruiting·SSavara Inc.·Phase 3·NCT06431776·5 enrolled
Clinical Trial of Inhaled Molgramostim Nebulizer Solution in Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Active, not recruiting·SSavara Inc.·Phase 3·NCT04544293·164 enrolled
Local Spraying of GM-CSF Via Bronchoscopy in the Treatment of Autoimmune Pulmonary Alveolar Proteinosis
Not yet recruiting·—·Phase 2·NCT06989333·10 enrolled
Evaluation of a Single Dose of Inhaled Sargramostim in Patients With Autoimmune Pulmonary Alveolar Proteinosis
Completed·—·Phase 1·NCT03006146·10 enrolled
Efficacy and Safety of Inhaled Molgramostim (rhGM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis
Completed·SSavara Inc.·Phase 2·NCT02702180·139 enrolled
Pioglitazone Therapy of Autoimmune Pulmonary Alveolar Proteinosis Autoimmune Pulmonary Alveolar Proteinosis
Completed·—·Phase 1·NCT03231033·3 enrolled
Safety Extension Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis
Terminated·SSavara Inc.·Phase 3·NCT03482752·60 enrolled
Sequential Therapy With WLL/Inhaling GM-CSF for Autoimmune Pulmonary Alveolar Proteinosis
Unknown status·—·Phase 2·NCT03316651·60 enrolled
Inhalation of Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) for Autoimmune Pulmonary Alveolar Proteinosis (PAP)
Unknown status·PPeking Union Medical College Hospital·Phase 2·NCT02243228·42 enrolled
Expanded Access to Inhaled Molgramostim Nebulizer Solution in Adults With Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Available·SSavara Inc.·N/A·NCT06546098

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)